“Breakthrough Therapies” Deserve Skepticism, Researchers Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Although drugs on the FDASIA-created expedited pathway may promise more than they can deliver, it will be difficult to reduce demand for such treatments awarded the designation, Boston researchers predict in a NEJM piece.